Position in GNLX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$52,814
+$22,472 QoQ
Shares Held
21,824
+94.2% QoQ
Ownership
0.048%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Catalyst Funds Management Pty Ltd holds $52,666,311 across 25 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
117,600 | $9,585,576 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
13,561 | $7,281,578 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
94,300 | $7,023,464 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
20,803 | $6,262,327 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
24,900 | $6,094,773 | |
| 6 | RPRX |
Royalty Pharma plc
|
79,910 | $4,480,553 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,001 | $3,477,606 | |
| 8 | INSM |
INSMED Inc
|
26,200 | $2,793,444 |
All Filings in GNLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $52,814 | 21,824 | Shares | Sole | 2026-05-11 | |
| 2025-03-31 | $30,342 | 11,238 | Shares | Sole | 2025-05-14 | |
| 2024-09-30 | $11,376 | 4,800 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $9,360 | 4,800 | Shares | Sole | 2024-12-18 | |
| No filing history on record for this holder in this stock. | ||||||